The Conversion Therapy of Chemotherapy Plus Camrelizumab in Metastatic Gastric Cancer

Sponsor
Quan Wang
Study ID
NCT04694183
Phase
PHASE2
Status
Completed

Conditions

  • Stomach Neoplasms

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Camrelizumab — DRUG
    200mg, intravenous drip administration, d1, every 3 weeks.
  • S-1 — DRUG
    Oral, d1-14, every 3 weeks.
  • Oxaliplatin — DRUG
    130mg/m² intravenous drip administration, d1, every 3 weeks(For patients with liver and/or para-aortic lymph node metastasis).
  • Paclitaxel — DRUG
    Intraperitoneal paclitaxel 20 mg/m² and intravenous paclitaxel 50 mg/m² on days 1 and 8, every 3 weeks(For patients with peritoneal metastasis ).

Study Details

Gastric cancer is one of the most common malignant tumors of the digestive tract. Gastric cancer patients diagnosed for the first time in China have a higher proportion of advanced stages and a higher postoperative metastasis rate.Studies have shown that patients with good pathological response after preoperative neoadjuvant therapy (such as tumor regression grade, TRG0 or 1) have a better prognosis.The purpose of this study is to treat patients with advanced gastric cancer who are difficult to perform R0 surgery with chemotherapy combined with immunotherapy. At the same time as the primary cancerous lesions are reduced, the distant metastatic lesions are effectively controlled in order to perform R0 surgery and to improve the survival rate of patients with advanced gastric cancer.

Key Dates

Start date
Aug 17, 2020
Status verified
Feb 2024
Primary completion
May 6, 2023
Completion
May 6, 2023

Study Design

Enrollment
37 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Conversion therapy
    Camrelizumab combined with chemotherapy selected per metastasis site.

Primary Outcome Measure

R0 resection rate [ Time Frame: Within 1 month of surgery. ]

Related Studies